CAR-T cell therapyFDA-approvedInvestigational
Tisagenlecleucel
How it works
Genetically modifies T cells to recognize and destroy cancer cells, providing a sustained immune response.
Cancer types
Leukemia— Relapsed or refractory B-cell ALL
Efficacy
In clinical trials, around 80% of patients achieved a complete response, with a median progression-free survival of approximately 6 months.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Study of Tisagenlecleucel in Patients with Leukemia or Lymphoma | Leukemia | phase-3 | — | Source → |
| Evaluating Tisagenlecleucel in Patients with High-Risk B-Cell Acute Lymphoblastic Leukemia | Leukemia | phase-2 | — | Source → |
| CAR T-cell therapy outcomes in young leukemia patients | Leukemia | observational | By day 28 postinfusion, 89% of patients achieved complete remission. | Source → |
| New Treatment Option for Relapsed Leukemia Patients | Leukemia | observational | All four patients achieved complete remission after the first InO cycle. | Source → |
| CAR-T Cell Therapy Improves Treatment for Relapsed ALL in Children and Young Adults | Leukemia | review | — | Source → |
| Cost-effectiveness of new leukemia treatment in children and young adults | Leukemia | review | The discounted incremental cost-effectiveness ratio (ICER) per quality-adjusted life year (QALY) gained for tisagenlecleucel compared with Clo-C and Blina averages was $38 837 and $25 569, respectively. | Source → |
| Comparing Two Treatments for Relapsed Leukemia in Children | Leukemia | phase-3 | Treatment with tisagenlecleucel was associated with a statistically significant higher likelihood of achieving CR (odds ratios: 6.71-9.76) and a lower hazard of death (hazard ratios: 0.26-0.32) than treatment with blinatumomab. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.